pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

Municipalities and States Grapple with Rising Health-Insurance Costs and Upcoming Medicaid Drug Pricing Deadline

Aug 18, 2026·read at STAT ↗RegulatoryNegative

Municipalities across the country are reporting that the cost of providing health insurance to their employees is becoming increasingly unsustainable, putting pressure on local budgets.

States are now facing a critical decision before a September 30 deadline: whether to join a federal program that would grant them "most‑favored nation" drug prices for Medicaid beneficiaries. Participation could lower drug spending but requires states to meet certain eligibility criteria.

The outcome of these choices could reshape Medicaid drug pricing dynamics, affecting both government health‑care expenditures and pharmaceutical revenue streams.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Government workers feel the squeeze on health care”

read at STAT ↗
453 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology2NSCLCPulmonology

related stories

  • May 6Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive
  • May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive
  • May 6Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive
  • May 6Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphomaonclive
  • May 6Dr Sznol on Biomarkers of Response in Metastatic Melanomaonclive